| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure
Forward-looking statements and third-party information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure
Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In... |
| 17 Jun 2026 |
8-K: Results of Operations and Financial Condition
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis |
| 11 May 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SHARE PURCHASE AGREEMENT (this “Agreement”) is entered into as of May 7, 2026 (the “Effective Date”), by and between TPG LSI Rise Orazio II, L.P. is a Delaware limited partnership (the “Investor”), and Odyssey Therapeutics, Inc., a ... |
Loading...